课题基金 / 基金详情

ANOMALOUS SIGNAL OF SOLVENT BROMIDES USED FOR PHASING OF LYSOZYME

ANOMALOUS SIGNAL OF SOLVENT BROMIDES USED FOR PHASING OF LYSOZYME
用于溶菌酶定相的溶剂溴化物的异常信号
批准号:
6205781
负责人:
ZBIGNIEW DAUTER
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-01 至 2000-08-31

项目摘要

项目成果

ZBIGNIEW DAUTER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
GPRTase catalyzes the pyrophosphorolysis of 5-purine nucleotides. Mutations in GPRTase are associated with Lesch-Hyhan disease, a major clinical neurodegenerative disorder. Parasitic organsims such as malaria and schistosomes cannot perform de novo purine biosynthesis and thus depend on the ability to salvage purines from host nucleotides. Thus HGPRTase is an excellent therapeutic target, provided that sufficient discrimination can be achieved between the human and parasitic enzymes. This is especially important in the case of malaria, as strains resistant to the existing antibiotics are becoming prevalent world wide. We have recently collected data on the complex between human HGPRTase bound to inorganic pyrophosphate and the transition state inhibitor to 2.2E on X-9B. The refined structure clearly identified the binding mode of the transition state analog, bound magnesium ion and pyrophosphate, as well as the interacting protein ligands. This structure also identifies the interactions responsible for stabilization of the oxycarbonium intermediate. We have very recently collected data to 2.0E of the malarial enzyme bound to the same set of inhibitory ligands. This represents the first report of the malarial enzyme crystallizing and will provide the opportunity to design malaria specific inhibitors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ANALYSIS OF CRYSTAL STRUCTURES AT VERY HIGH RESOLUTION
  • 批准号:
    8361715
  • 项目类别:
  • 资助金额:
    $1.1万
  • 财政年份:
    2011
  • 负责人:
    ZBIGNIEW DAUTER
  • 依托单位:
XRAY DIFFRACTION OPERATIONS ON X9B
CRYSTAL STRUCTURE OF HUMAN RHOA GDP RHOGDI COMPLEX & ITS BIOLOGICAL IMPLICATIONS
ANOMALOUS SIGNAL OF SULFUR AS TOOL FOR SOLVING PROTEIN CRYSTAL STRUCTURES?
海外基金